{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:47:55Z","timestamp":1790740075692,"version":"4.1.0"},"reference-count":104,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.3960\/jslrt.17019","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T22:15:27Z","timestamp":1514326527000},"page":"109-119","source":"Crossref","is-referenced-by-count":28,"title":["Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma"],"prefix":"10.3960","volume":"57","author":[{"given":"Manabu","family":"Fujisawa","sequence":"first","affiliation":[{"name":"Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba"},{"name":"Department of Hematology, Faculty of Medicine, University of Tsukuba"},{"name":"Department of Hematology, University of Tsukuba Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba"},{"name":"Department of Hematology, Faculty of Medicine, University of Tsukuba"},{"name":"Department of Hematology, University of Tsukuba Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Vose J, Armitage J, Weisenburger D, International TCLP: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130, 2008","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148: 673-689, 2010","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"3","unstructured":"3 Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, <i>et al<\/i>.: Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119: 2837-2843, 2012"},{"key":"4","unstructured":"4 Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, <i>et al<\/i>.: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int 58: 89-97, 2008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, <i>et al<\/i>.: IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126: 1741-1752, 2015","DOI":"10.1182\/blood-2015-05-644591"},{"key":"6","unstructured":"6 Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, <i>et al<\/i>.: Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 32: 16-21, 2014"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, <i>et al<\/i>.: Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 102, e148-e151, 2017","DOI":"10.3324\/haematol.2016.158428"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, <i>et al<\/i>.: Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk 17, 193-200, 2017","DOI":"10.1016\/j.clml.2016.10.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ohtani H, Komeno T, Agatsuma Y, Kobayashi M, Noguchi M, <i>et al<\/i>.: Follicular Dendritic Cell Meshwork in Angioimmunoblastic T-Cell Lymphoma Is Characterized by Accumulation of CXCL13(+) Cells. J Clin Exp Hematop 55: 61-69, 2015","DOI":"10.3960\/jslrt.55.61"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, <i>et al<\/i>.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016","DOI":"10.1182\/blood-2016-01-643569"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, <i>et al<\/i>.: Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 33: 682-690, 2009","DOI":"10.1097\/PAS.0b013e3181971591"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, <i>et al<\/i>.: Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120: 1466-1469, 2012","DOI":"10.1182\/blood-2012-02-408542"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, <i>et al<\/i>.: Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46: 171-175, 2014","DOI":"10.1038\/ng.2872"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, <i>et al<\/i>.: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 92: 1059-1066, 2007","DOI":"10.3324\/haematol.10864"},{"key":"15","unstructured":"15 Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, <i>et al<\/i>.: Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 103: 236-241, 2004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Chen L, Flies DB: Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13: 227-242, 2013","DOI":"10.1038\/nri3405"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, <i>et al<\/i>.: PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 11: 535-542, 2010","DOI":"10.1038\/ni.1877"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, <i>et al<\/i>.: Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 450: 299-303, 2007","DOI":"10.1038\/nature06253"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ellyard JI, Chia T, Rodriguez-Pinilla SM, Martin JL, Hu X, <i>et al<\/i>.: Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood 120: 812-821, 2012","DOI":"10.1182\/blood-2011-07-365130"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Crotty S: T follicular helper cell differentiation, function, and roles in disease. Immunity 41: 529-542, 2014","DOI":"10.1016\/j.immuni.2014.10.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Nishizawa S, Sakata-Yanagimoto M, Hattori K, Muto H, Nguyen T, <i>et al<\/i>.: BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. Int J Hematol 105, 465-469, 2016","DOI":"10.1007\/s12185-016-2159-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, <i>et al<\/i>.: Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 4: 117 e264, 2014","DOI":"10.1038\/bcj.2014.83"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Schwartzberg PL, Mueller KL, Qi H, Cannons JL: SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 9: 39-46, 2009","DOI":"10.1038\/nri2456"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 McCausland MM, Yusuf I, Tran H, Ono N, Yanagi Y, <i>et al<\/i>.: SAP regulation of follicular helper CD4 T cell development and humoral immunity is independent of SLAM and Fyn kinase. J Immunol 178: 817-828, 2007","DOI":"10.4049\/jimmunol.178.2.817"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Sayos J, Wu C, Morra M, Wang N, Zhang X, <i>et al<\/i>.: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395: 462-469, 1998","DOI":"10.1038\/26683"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Allen CD, Cyster JG: Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 20: 14-25, 2008","DOI":"10.1016\/j.smim.2007.12.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Palomero T: Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46: 166-170, 2014","DOI":"10.1038\/ng.2873"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Yoo HY, Sung MK, Lee SH, Kim S, Lee H, <i>et al<\/i>.: A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nature Genetics 46, 371-375, 2014","DOI":"10.1038\/ng.2916"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, <i>et al<\/i>.: Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46: 171-175, 2014","DOI":"10.1038\/ng.2872"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, <i>et al<\/i>.: IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119: 1901-1903, 2012","DOI":"10.1182\/blood-2011-11-391748"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Sakata-Yanagimoto M: Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 102, 523-527 2015","DOI":"10.1007\/s12185-015-1738-8"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Rasmussen KD, Helin K: Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 30: 733-750, 2016","DOI":"10.1101\/gad.276568.115"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, <i>et al<\/i>.: Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301, 2009","DOI":"10.1056\/NEJMoa0810069"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Yang L, Rau R, Goodell MA: DNMT3A in haematological malignancies. Nat Rev Cancer 15: 152-165, 2015","DOI":"10.1038\/nrc3895"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Koya J, Kataoka K, Sato T, Bando M, Kato Y, <i>et al<\/i>.: DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun 7: 10924, 2016","DOI":"10.1038\/ncomms10924"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Zhang X, Su J, Jeong M, Ko M, Huang Y, <i>et al<\/i>.: DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet 48: 1014-1023, 2016","DOI":"10.1038\/ng.3610"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Scourzic L, Couronne L, Pedersen MT, Della Valle V, Diop M, <i>et al<\/i>.: DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia 30: 1388-1398, 2016","DOI":"10.1038\/leu.2016.29"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, <i>et al<\/i>.: Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31: 272-281, 2017","DOI":"10.1038\/leu.2016.275"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, <i>et al<\/i>.: The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci U S A 113: 15084-15089, 2016","DOI":"10.1073\/pnas.1617929114"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Inoue S, Lemonnier F, Mak TW: Roles of IDH1\/2 and TET2 mutations in myeloid disorders. Int J Hematol 103: 627-633, 2016","DOI":"10.1007\/s12185-016-1973-7"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, <i>et al<\/i>.: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567, 2010","DOI":"10.1016\/j.ccr.2010.11.015"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, <i>et al<\/i>.: Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46: 166-170, 2014","DOI":"10.1038\/ng.2873"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Yoo HY, Sung MK, Lee SH, Kim S, Lee H, <i>et al<\/i>.: A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46: 371-375, 2014","DOI":"10.1038\/ng.2916"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, <i>et al<\/i>.: Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 46: 583-587, 2014","DOI":"10.1038\/ng.2984"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, <i>et al<\/i>.: Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 53, 911-6, 2014","DOI":"10.1002\/gcc.22202"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, <i>et al<\/i>.: Variegated RHOA mutations in adult T-cell leukemia\/lymphoma. Blood 127: 594-604, 2016","DOI":"10.1182\/blood-2015-06-644948"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 420: 629-635, 2002","DOI":"10.1038\/nature01148"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, <i>et al<\/i>.: Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128: 1490-1502, 2016","DOI":"10.1182\/blood-2016-02-698977"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Rohr J, Guo S, Huo J, Bouska A, Lachel C, <i>et al<\/i>.: Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30: 1062-1070, 2016","DOI":"10.1038\/leu.2015.357"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, <i>et al<\/i>.: Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet 47: 1304-1315, 2015","DOI":"10.1038\/ng.3415"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Gomez-Rodriguez J, Readinger JA, Viorritto IC, Mueller KL, Houghtling RA, <i>et al<\/i>.: Tec kinases, actin, and cell adhesion. Immunol Rev 218: 45-64, 2007","DOI":"10.1111\/j.1600-065X.2007.00534.x"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA: CD28 Costimulation: From Mechanism to Therapy. Immunity 44: 973-988, 2016","DOI":"10.1016\/j.immuni.2016.04.020"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Lee SH, Kim JS, Kim J, Kim SJ, Kim WS, <i>et al<\/i>.: A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica 100: e505-507, 2015","DOI":"10.3324\/haematol.2015.133074"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Yoo HY, Kim P, Kim WS, Lee SH, Kim S, <i>et al<\/i>.: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 101: 757-763, 2016","DOI":"10.3324\/haematol.2015.139253"},{"key":"55","unstructured":"55 Gong Q, Wang C, Rohr J, Feldman AL, Chan WC, <i>et al<\/i>.: Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo <i>et al<\/i>. Haematologica 101: e269-270, 2016"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, <i>et al<\/i>.: Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc Natl Acad Sci U S A 114: 764-769, 2017","DOI":"10.1073\/pnas.1608839114"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Boddicker RL, Razidlo GL, Dasari S, Zeng Y, Hu G, <i>et al<\/i>.: Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128: 1234-1245, 2016","DOI":"10.1182\/blood-2016-03-707141"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A: Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20: 313-318, 2006","DOI":"10.1038\/sj.leu.2404045"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, <i>et al<\/i>.: The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 207: 1031-1044, 2010","DOI":"10.1084\/jem.20092042"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Gaulard P, de Leval L: The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol 24: 49-60, 2014","DOI":"10.1016\/j.semcancer.2013.11.004"},{"key":"61","unstructured":"61 Shimoyama M, Minato K: [Clinical, cytological and immunological analysis of T-cell type lymphoid malignancies: a classification of T-cell type lymphoid malignancy (author\u2019s transl)]. Rinsho Ketsueki 20: 1056-1069, 1979"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, <i>et al<\/i>.: The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109: 4952-4963, 2007","DOI":"10.1182\/blood-2006-10-055145"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, <i>et al<\/i>.: Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67: 10703-10710, 2007","DOI":"10.1158\/0008-5472.CAN-07-1708"},{"key":"64","unstructured":"64 Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, <i>et al<\/i>.: Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 37: 816-826, 2013"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Moroch J, Copie-Bergman C, de Leval L, Plonquet A, Martin-Garcia N, <i>et al<\/i>.: Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol 36: 1636-1646, 2012","DOI":"10.1097\/PAS.0b013e318268d9ff"},{"key":"66","unstructured":"66 Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, <i>et al<\/i>.: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 138: 44-53, 2007"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, <i>et al<\/i>.: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials. Blood 111: 4463-4470, 2008","DOI":"10.1182\/blood-2007-08-105759"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Suefuji N, Niino D, Arakawa F, Karube K, Kimura Y, <i>et al<\/i>.: Clinicopathological analysis of a composite lymphoma containing both T- and B-cell lymphomas. Pathol Int 62: 690-698, 2012","DOI":"10.1111\/j.1440-1827.2012.02858.x"},{"key":"69","unstructured":"69 Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, <i>et al<\/i>.: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 31: 1077-1088, 2007"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Willenbrock K, Brauninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 138: 733-739, 2007","DOI":"10.1111\/j.1365-2141.2007.06725.x"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, <i>et al<\/i>.: Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20: 1472-1478, 2014","DOI":"10.1038\/nm.3733"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman, PV, <i>et al<\/i>.: Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371: 2488-2498, 2014","DOI":"10.1056\/NEJMoa1408617"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, <i>et al<\/i>.: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371: 2477-2487, 2014","DOI":"10.1056\/NEJMoa1409405"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, <i>et al<\/i>.: Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J Med 371, 2477-87, 2014","DOI":"10.1056\/NEJMoa1409405"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, <i>et al<\/i>.: Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med 371, 2488-98, 2014","DOI":"10.1056\/NEJMoa1408617"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Nguyen TB, Sakata-Yanagimoto M, Asabe Y, Matsubara D, Kano J, <i>et al<\/i>.: Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7: e516, 2017","DOI":"10.1038\/bcj.2016.122"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, <i>et al<\/i>.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271, 2004","DOI":"10.1126\/science.1102160"},{"key":"78","unstructured":"78 Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, <i>et al<\/i>.: Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105, 2011"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, <i>et al<\/i>.: Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20: 246-259, 2011","DOI":"10.1016\/j.ccr.2011.06.029"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, <i>et al<\/i>.: Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4: 1088-1101, 2014","DOI":"10.1158\/2159-8290.CD-14-0104"},{"key":"81","unstructured":"81 Malik SM, Liu K, Qiang X, Sridhara R, Tang S, <i>et al<\/i>.: Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 16: 4921-4927, 2010"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, <i>et al<\/i>.: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117: 5827-5834, 2011","DOI":"10.1182\/blood-2010-10-312603"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Coiffier B, Pro B, Prince HM, Foss F, Sokol L, <i>et al<\/i>.: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30: 631-636, 2012","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"84","unstructured":"84 O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, <i>et al<\/i>.: Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol 33: 2492-2499, 2015"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, <i>et al<\/i>.: Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123: 3095-3100, 2014","DOI":"10.1182\/blood-2013-12-542142"},{"key":"86","unstructured":"86 Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, <i>et al<\/i>.: Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 48: 3223-3231, 2012"},{"key":"87","unstructured":"87 Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, <i>et al<\/i>.: Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 31: 104-110, 2013"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Toumishey E, Prasad A, Dueck G, Chua N, Finch D, <i>et al<\/i>.: Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121: 716-723, 2015","DOI":"10.1002\/cncr.29103"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Tsukasaki K, Tobinai K, Uchida T, Maeda Y, Shibayama H, <i>et al<\/i>. Phase 1\/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). J Clin Oncol 34: 7542, 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.7542"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, <i>et al<\/i>.: Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 97: 1594-1602, 2012","DOI":"10.3324\/haematol.2011.061507"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Chen XG, Huang H, Tian Y, Guo CC, Liang CY, <i>et al<\/i>.: Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen. Chin J Cancer 30: 731-738, 2011","DOI":"10.5732\/cjc.011.10071"},{"key":"92","unstructured":"92 Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, <i>et al<\/i>.: Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 45: 311-316, 2010"},{"key":"93","unstructured":"93 Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, <i>et al<\/i>.: High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26: 218-224, 2008"},{"key":"94","unstructured":"94 Schetelig J, Fetscher S, Reichle A, Berdel WE, Beguin Y, <i>et al<\/i>.: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88: 1272-1278, 2003"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Ellin F, Landstrom J, Jerkeman M, Relander T: Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124: 1570-1577, 2014","DOI":"10.1182\/blood-2014-04-573089"},{"key":"96","unstructured":"96 d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, <i>et al<\/i>.: Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30: 3093-3099, 2012"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, <i>et al<\/i>.: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533-1538, 2006","DOI":"10.1038\/sj.leu.2404306"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, <i>et al<\/i>.: Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19: 958-963, 2008","DOI":"10.1093\/annonc\/mdn022"},{"key":"99","unstructured":"99 Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, <i>et al<\/i>.: First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 6: e452, 2016"},{"key":"100","unstructured":"100 Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, <i>et al<\/i>.: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27: 3951-3958, 2009"},{"key":"101","unstructured":"101 Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, <i>et al<\/i>.: Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26: 520-526, 2012"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, <i>et al<\/i>.: Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31: 3100-3109, 2013","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"103","unstructured":"103 Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, <i>et al<\/i>.: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26: 2264-2271, 2008"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, <i>et al<\/i>.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22: 2172-2176, 2004","DOI":"10.1200\/JCO.2004.12.050"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T07:55:41Z","timestamp":1660204541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.17019","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}